#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Aggregatibacter actinomycetemcomitans
3-1	17-32	Aggregatibacter	person[3]	new[3]	coref	6-1[14_3]
3-2	33-54	actinomycetemcomitans	person[3]	new[3]	_	_

#Text=is a Gram-negative member of the human oral microbiota and is involved in human infections and diseases .
4-1	55-57	is	_	_	_	_
4-2	58-59	a	person[4]	new[4]	_	_
4-3	60-73	Gram-negative	person[4]	new[4]	_	_
4-4	74-80	member	person[4]	new[4]	_	_
4-5	81-83	of	person[4]	new[4]	_	_
4-6	84-87	the	person[4]|object[5]	new[4]|new[5]	_	_
4-7	88-93	human	person[4]|object[5]	new[4]|new[5]	_	_
4-8	94-98	oral	person[4]|object[5]	new[4]|new[5]	_	_
4-9	99-109	microbiota	person[4]|object[5]	new[4]|new[5]	_	_
4-10	110-113	and	_	_	_	_
4-11	114-116	is	_	_	_	_
4-12	117-125	involved	_	_	_	_
4-13	126-128	in	_	_	_	_
4-14	129-134	human	abstract[6]	new[6]	_	_
4-15	135-145	infections	abstract[6]	new[6]	_	_
4-16	146-149	and	_	_	_	_
4-17	150-158	diseases	abstract	new	coref	5-3[9_0]
4-18	159-160	.	_	_	_	_

#Text=One of these diseases is periodontitis , characterized by destruction of tooth-supporting periodontal tissues due to an inflammatory response .
5-1	161-164	One	abstract[8]	new[8]	coref	5-6[0_8]
5-2	165-167	of	abstract[8]	new[8]	_	_
5-3	168-173	these	abstract[8]|abstract[9]	new[8]|giv[9]	_	_
5-4	174-182	diseases	abstract[8]|abstract[9]	new[8]|giv[9]	_	_
5-5	183-185	is	_	_	_	_
5-6	186-199	periodontitis	abstract	giv	coref	9-28[40_0]
5-7	200-201	,	_	_	_	_
5-8	202-215	characterized	_	_	_	_
5-9	216-218	by	_	_	_	_
5-10	219-230	destruction	event[11]	new[11]	_	_
5-11	231-233	of	event[11]	new[11]	_	_
5-12	234-250	tooth-supporting	event[11]	new[11]	_	_
5-13	251-262	periodontal	event[11]|object[12]	new[11]|new[12]	_	_
5-14	263-270	tissues	event[11]|object[12]	new[11]|new[12]	_	_
5-15	271-274	due	event[11]|object[12]	new[11]|new[12]	_	_
5-16	275-277	to	_	_	_	_
5-17	278-280	an	abstract[13]	new[13]	coref	8-8[25_13]
5-18	281-293	inflammatory	abstract[13]	new[13]	_	_
5-19	294-302	response	abstract[13]	new[13]	_	_
5-20	303-304	.	_	_	_	_

#Text=A. actinomycetemcomitans
6-1	305-307	A.	person[14]	giv[14]	coref	10-21[0_14]
6-2	308-329	actinomycetemcomitans	person[14]	giv[14]	_	_

#Text=possesses several virulence factors , of which the production of the RTX ( repeats-in-toxin ) leukotoxin ( LtxA ) has received much attention .
7-1	330-339	possesses	_	_	_	_
7-2	340-347	several	abstract[16]	new[16]	coref	19-50[133_16]
7-3	348-357	virulence	abstract|abstract[16]	new|new[16]	coref	10-35[50_0]
7-4	358-365	factors	abstract[16]	new[16]	_	_
7-5	366-367	,	_	_	_	_
7-6	368-370	of	_	_	_	_
7-7	371-376	which	_	_	_	_
7-8	377-380	the	abstract[17]	new[17]	coref	19-17[0_17]
7-9	381-391	production	abstract[17]	new[17]	_	_
7-10	392-394	of	abstract[17]	new[17]	_	_
7-11	395-398	the	abstract[17]|abstract[18]	new[17]|new[18]	_	_
7-12	399-402	RTX	abstract[17]|abstract[18]	new[17]|new[18]	_	_
7-13	403-404	(	abstract[17]	new[17]	_	_
7-14	405-421	repeats-in-toxin	abstract[17]	new[17]	_	_
7-15	422-423	)	abstract[17]	new[17]	_	_
7-16	424-434	leukotoxin	abstract[17]	new[17]	_	_
7-17	435-436	(	_	_	_	_
7-18	437-441	LtxA	object	new	coref	8-1
7-19	442-443	)	_	_	_	_
7-20	444-447	has	_	_	_	_
7-21	448-456	received	_	_	_	_
7-22	457-461	much	abstract[20]	new[20]	_	_
7-23	462-471	attention	abstract[20]	new[20]	_	_
7-24	472-473	.	_	_	_	_

#Text=LtxA induces cell lysis , degranulation and an inflammatory response in human leukocytes by interaction with the β2-integrins in the cell membrane of human immune cells .
8-1	474-478	LtxA	abstract	giv	coref	9-10
8-2	479-486	induces	_	_	_	_
8-3	487-491	cell	place|abstract[23]	new|new[23]	coref|coref|coref|coref	14-8|14-9[0_23]|14-8|14-9[0_23]
8-4	492-497	lysis	abstract[23]	new[23]	_	_
8-5	498-499	,	_	_	_	_
8-6	500-513	degranulation	event	new	_	_
8-7	514-517	and	_	_	_	_
8-8	518-520	an	abstract[25]	giv[25]	_	_
8-9	521-533	inflammatory	abstract[25]	giv[25]	_	_
8-10	534-542	response	abstract[25]	giv[25]	_	_
8-11	543-545	in	abstract[25]	giv[25]	_	_
8-12	546-551	human	abstract[25]|substance[26]	giv[25]|new[26]	_	_
8-13	552-562	leukocytes	abstract[25]|substance[26]	giv[25]|new[26]	_	_
8-14	563-565	by	_	_	_	_
8-15	566-577	interaction	abstract[27]	new[27]	_	_
8-16	578-582	with	abstract[27]	new[27]	_	_
8-17	583-586	the	abstract[27]|substance[28]	new[27]|new[28]	_	_
8-18	587-599	β2-integrins	abstract[27]|substance[28]	new[27]|new[28]	_	_
8-19	600-602	in	abstract[27]|substance[28]	new[27]|new[28]	_	_
8-20	603-606	the	abstract[27]|substance[28]|place[29]	new[27]|new[28]|new[29]	_	_
8-21	607-611	cell	abstract[27]|substance[28]|place[29]	new[27]|new[28]|new[29]	_	_
8-22	612-620	membrane	abstract[27]|substance[28]|place[29]	new[27]|new[28]|new[29]	_	_
8-23	621-623	of	abstract[27]|substance[28]|place[29]	new[27]|new[28]|new[29]	_	_
8-24	624-629	human	abstract[27]|substance[28]|place[29]|place[30]	new[27]|new[28]|new[29]|new[30]	coref	14-13[79_30]
8-25	630-636	immune	abstract[27]|substance[28]|place[29]|place[30]	new[27]|new[28]|new[29]|new[30]	_	_
8-26	637-642	cells	abstract[27]|substance[28]|place[29]|place[30]	new[27]|new[28]|new[29]|new[30]	_	_
8-27	643-644	.	_	_	_	_

#Text=A 530-bp deletion in the promoter region of the LtxA gene operon was identified in the original JP2 strain , cultured from a young individual diagnosed with juvenile periodontitis .
9-1	645-646	A	abstract[31]	new[31]	coref	10-14[45_31]
9-2	647-653	530-bp	abstract[31]	new[31]	_	_
9-3	654-662	deletion	abstract[31]	new[31]	_	_
9-4	663-665	in	abstract[31]	new[31]	_	_
9-5	666-669	the	abstract[31]|place[33]	new[31]|new[33]	_	_
9-6	670-678	promoter	abstract[31]|person|place[33]	new[31]|new|new[33]	_	_
9-7	679-685	region	abstract[31]|place[33]	new[31]|new[33]	_	_
9-8	686-688	of	abstract[31]|place[33]	new[31]|new[33]	_	_
9-9	689-692	the	abstract[31]|place[33]|abstract[36]	new[31]|new[33]|new[36]	_	_
9-10	693-697	LtxA	abstract[31]|place[33]|object|abstract[36]	new[31]|new[33]|giv|new[36]	coref	14-24[81_0]
9-11	698-702	gene	abstract[31]|place[33]|abstract|abstract[36]	new[31]|new[33]|new|new[36]	_	_
9-12	703-709	operon	abstract[31]|place[33]|abstract[36]	new[31]|new[33]|new[36]	_	_
9-13	710-713	was	_	_	_	_
9-14	714-724	identified	_	_	_	_
9-15	725-727	in	_	_	_	_
9-16	728-731	the	abstract[38]	new[38]	coref	14-41[86_38]
9-17	732-740	original	abstract[38]	new[38]	_	_
9-18	741-744	JP2	abstract|abstract[38]	new|new[38]	_	_
9-19	745-751	strain	abstract[38]	new[38]	_	_
9-20	752-753	,	_	_	_	_
9-21	754-762	cultured	_	_	_	_
9-22	763-767	from	_	_	_	_
9-23	768-769	a	person[39]	new[39]	_	_
9-24	770-775	young	person[39]	new[39]	_	_
9-25	776-786	individual	person[39]	new[39]	_	_
9-26	787-796	diagnosed	_	_	_	_
9-27	797-801	with	_	_	_	_
9-28	802-810	juvenile	abstract[40]	giv[40]	coref	12-27[0_40]
9-29	811-824	periodontitis	abstract[40]	giv[40]	_	_
9-30	825-826	.	_	_	_	_

#Text=This discovery marked the beginning of an era , where the detection of the 530-bp deletion categorized highly leukotoxic A. actinomycetemcomitans strains as a member of the JP2 clone of A. actinomycetemcomitans , possessing enhanced virulence .
10-1	827-831	This	event[41]	new[41]	_	_
10-2	832-841	discovery	event[41]	new[41]	_	_
10-3	842-848	marked	_	_	_	_
10-4	849-852	the	abstract[42]	new[42]	_	_
10-5	853-862	beginning	abstract[42]	new[42]	_	_
10-6	863-865	of	abstract[42]	new[42]	_	_
10-7	866-868	an	abstract[42]|time[43]	new[42]|new[43]	_	_
10-8	869-872	era	abstract[42]|time[43]	new[42]|new[43]	_	_
10-9	873-874	,	_	_	_	_
10-10	875-880	where	_	_	_	_
10-11	881-884	the	abstract[44]	new[44]	_	_
10-12	885-894	detection	abstract[44]	new[44]	_	_
10-13	895-897	of	abstract[44]	new[44]	_	_
10-14	898-901	the	abstract[44]|abstract[45]	new[44]|giv[45]	coref	15-21[93_45]
10-15	902-908	530-bp	abstract[44]|abstract[45]	new[44]|giv[45]	_	_
10-16	909-917	deletion	abstract[44]|abstract[45]	new[44]|giv[45]	_	_
10-17	918-929	categorized	_	_	_	_
10-18	930-936	highly	abstract[47]	new[47]	coref	16-3[100_47]
10-19	937-947	leukotoxic	abstract[47]	new[47]	_	_
10-20	948-950	A.	abstract[47]	new[47]	_	_
10-21	951-972	actinomycetemcomitans	person|abstract[47]	giv|new[47]	coref	10-31[49_0]
10-22	973-980	strains	abstract[47]	new[47]	_	_
10-23	981-983	as	_	_	_	_
10-24	984-985	a	_	_	_	_
10-25	986-992	member	_	_	_	_
10-26	993-995	of	_	_	_	_
10-27	996-999	the	abstract[48]	new[48]	_	_
10-28	1000-1003	JP2	abstract[48]	new[48]	_	_
10-29	1004-1009	clone	abstract[48]	new[48]	_	_
10-30	1010-1012	of	abstract[48]	new[48]	_	_
10-31	1013-1015	A.	abstract[48]|person[49]	new[48]|giv[49]	coref	11-15[54_49]
10-32	1016-1037	actinomycetemcomitans	abstract[48]|person[49]	new[48]|giv[49]	_	_
10-33	1038-1039	,	_	_	_	_
10-34	1040-1050	possessing	_	_	_	_
10-35	1051-1059	enhanced	abstract[50]	giv[50]	ana	11-7[0_50]
10-36	1060-1069	virulence	abstract[50]	giv[50]	_	_
10-37	1070-1071	.	_	_	_	_

#Text=Based on in vitro studies , it was reported that the JP2 genotype of A. actinomycetemcomitans has a 10 – 20 fold higher lytic activity than the non-JP2 genotypes of A. actinomycetemcomitans .
11-1	1072-1077	Based	_	_	_	_
11-2	1078-1080	on	_	_	_	_
11-3	1081-1083	in	_	_	_	_
11-4	1084-1089	vitro	event[51]	new[51]	coref	12-3[60_51]
11-5	1090-1097	studies	event[51]	new[51]	_	_
11-6	1098-1099	,	_	_	_	_
11-7	1100-1102	it	abstract	giv	_	_
11-8	1103-1106	was	_	_	_	_
11-9	1107-1115	reported	_	_	_	_
11-10	1116-1120	that	_	_	_	_
11-11	1121-1124	the	abstract[53]	new[53]	coref	12-14[63_53]
11-12	1125-1128	JP2	abstract[53]	new[53]	_	_
11-13	1129-1137	genotype	abstract[53]	new[53]	_	_
11-14	1138-1140	of	abstract[53]	new[53]	_	_
11-15	1141-1143	A.	abstract[53]|person[54]	new[53]|giv[54]	coref	11-31[59_54]
11-16	1144-1165	actinomycetemcomitans	abstract[53]|person[54]	new[53]|giv[54]	_	_
11-17	1166-1169	has	_	_	_	_
11-18	1170-1171	a	abstract[57]	new[57]	coref	18-28[117_57]
11-19	1172-1174	10	place[56]|abstract[57]	new[56]|new[57]	_	_
11-20	1175-1176	–	place[56]|abstract[57]	new[56]|new[57]	_	_
11-21	1177-1179	20	quantity|place[56]|abstract[57]	new|new[56]|new[57]	_	_
11-22	1180-1184	fold	place[56]|abstract[57]	new[56]|new[57]	_	_
11-23	1185-1191	higher	abstract[57]	new[57]	_	_
11-24	1192-1197	lytic	abstract[57]	new[57]	_	_
11-25	1198-1206	activity	abstract[57]	new[57]	_	_
11-26	1207-1211	than	abstract[57]	new[57]	_	_
11-27	1212-1215	the	abstract[57]|abstract[58]	new[57]|new[58]	_	_
11-28	1216-1223	non-JP2	abstract[57]|abstract[58]	new[57]|new[58]	_	_
11-29	1224-1233	genotypes	abstract[57]|abstract[58]	new[57]|new[58]	_	_
11-30	1234-1236	of	abstract[57]|abstract[58]	new[57]|new[58]	_	_
11-31	1237-1239	A.	abstract[57]|abstract[58]|person[59]	new[57]|new[58]|giv[59]	coref	12-18[64_59]
11-32	1240-1261	actinomycetemcomitans	abstract[57]|abstract[58]|person[59]	new[57]|new[58]|giv[59]	_	_
11-33	1262-1263	.	_	_	_	_

#Text=Furthermore , longitudinal clinical studies reported a clear correlation between being carrier of the JP2 genotype of A. actinomycetemcomitans and having an increased risk of developing periodontitis at a young age .
12-1	1264-1275	Furthermore	_	_	_	_
12-2	1276-1277	,	_	_	_	_
12-3	1278-1290	longitudinal	event[60]	giv[60]	coref	13-15[72_60]
12-4	1291-1299	clinical	event[60]	giv[60]	_	_
12-5	1300-1307	studies	event[60]	giv[60]	_	_
12-6	1308-1316	reported	_	_	_	_
12-7	1317-1318	a	abstract[61]	new[61]	_	_
12-8	1319-1324	clear	abstract[61]	new[61]	_	_
12-9	1325-1336	correlation	abstract[61]	new[61]	_	_
12-10	1337-1344	between	_	_	_	_
12-11	1345-1350	being	_	_	_	_
12-12	1351-1358	carrier	organization[62]	new[62]	_	_
12-13	1359-1361	of	organization[62]	new[62]	_	_
12-14	1362-1365	the	organization[62]|abstract[63]	new[62]|giv[63]	_	_
12-15	1366-1369	JP2	organization[62]|abstract[63]	new[62]|giv[63]	_	_
12-16	1370-1378	genotype	organization[62]|abstract[63]	new[62]|giv[63]	_	_
12-17	1379-1381	of	organization[62]|abstract[63]	new[62]|giv[63]	_	_
12-18	1382-1384	A.	organization[62]|abstract[63]|person[64]	new[62]|giv[63]|giv[64]	coref	13-6[69_64]
12-19	1385-1406	actinomycetemcomitans	organization[62]|abstract[63]|person[64]	new[62]|giv[63]|giv[64]	_	_
12-20	1407-1410	and	_	_	_	_
12-21	1411-1417	having	_	_	_	_
12-22	1418-1420	an	abstract[65]	new[65]	_	_
12-23	1421-1430	increased	abstract[65]	new[65]	_	_
12-24	1431-1435	risk	abstract[65]	new[65]	_	_
12-25	1436-1438	of	_	_	_	_
12-26	1439-1449	developing	_	_	_	_
12-27	1450-1463	periodontitis	abstract	giv	_	_
12-28	1464-1466	at	_	_	_	_
12-29	1467-1468	a	abstract[67]	new[67]	_	_
12-30	1469-1474	young	abstract[67]	new[67]	_	_
12-31	1475-1478	age	abstract[67]	new[67]	_	_
12-32	1479-1480	.	_	_	_	_

#Text=Often the leukotoxic potential of A. actinomycetemcomitans is characterized by the leukotoxicity in in vitro studies .
13-1	1481-1486	Often	_	_	_	_
13-2	1487-1490	the	abstract[68]	new[68]	_	_
13-3	1491-1501	leukotoxic	abstract[68]	new[68]	_	_
13-4	1502-1511	potential	abstract[68]	new[68]	_	_
13-5	1512-1514	of	abstract[68]	new[68]	_	_
13-6	1515-1517	A.	abstract[68]|person[69]	new[68]|giv[69]	coref	14-43[0_69]
13-7	1518-1539	actinomycetemcomitans	abstract[68]|person[69]	new[68]|giv[69]	_	_
13-8	1540-1542	is	_	_	_	_
13-9	1543-1556	characterized	_	_	_	_
13-10	1557-1559	by	_	_	_	_
13-11	1560-1563	the	abstract[70]	new[70]	coref	14-1[73_70]
13-12	1564-1577	leukotoxicity	abstract[70]	new[70]	_	_
13-13	1578-1580	in	abstract[70]	new[70]	_	_
13-14	1581-1583	in	abstract[70]	new[70]	_	_
13-15	1584-1589	vitro	abstract[70]|organization|event[72]	new[70]|new|giv[72]	coref|coref	19-2[120_72]|19-2[120_72]
13-16	1590-1597	studies	abstract[70]|event[72]	new[70]|giv[72]	_	_
13-17	1598-1599	.	_	_	_	_

#Text=This leukotoxicity is determined by use of cell lysis assays , where human immune cells are exposed either to the bacteria or to purified LtxA , and most often the leukotoxicity is correlated with the JP2 or non-JP2 genotype of the A. actinomycetemcomitans strain .
14-1	1600-1604	This	abstract[73]	giv[73]	coref	14-30[82_73]
14-2	1605-1618	leukotoxicity	abstract[73]	giv[73]	_	_
14-3	1619-1621	is	_	_	_	_
14-4	1622-1632	determined	_	_	_	_
14-5	1633-1635	by	_	_	_	_
14-6	1636-1639	use	abstract[74]	new[74]	_	_
14-7	1640-1642	of	abstract[74]	new[74]	_	_
14-8	1643-1647	cell	abstract[74]|place|abstract[77]	new[74]|giv|new[77]	coref|coref	16-18|16-18
14-9	1648-1653	lysis	abstract[74]|abstract|abstract[77]	new[74]|giv|new[77]	coref	16-19
14-10	1654-1660	assays	abstract[74]|abstract[77]	new[74]|new[77]	_	_
14-11	1661-1662	,	_	_	_	_
14-12	1663-1668	where	_	_	_	_
14-13	1669-1674	human	object[79]	giv[79]	_	_
14-14	1675-1681	immune	abstract|object[79]	new|giv[79]	_	_
14-15	1682-1687	cells	object[79]	giv[79]	_	_
14-16	1688-1691	are	_	_	_	_
14-17	1692-1699	exposed	_	_	_	_
14-18	1700-1706	either	animal[80]	new[80]	_	_
14-19	1707-1709	to	animal[80]	new[80]	_	_
14-20	1710-1713	the	animal[80]	new[80]	_	_
14-21	1714-1722	bacteria	animal[80]	new[80]	_	_
14-22	1723-1725	or	_	_	_	_
14-23	1726-1728	to	_	_	_	_
14-24	1729-1737	purified	object[81]	giv[81]	coref	18-9[114_81]
14-25	1738-1742	LtxA	object[81]	giv[81]	_	_
14-26	1743-1744	,	_	_	_	_
14-27	1745-1748	and	_	_	_	_
14-28	1749-1753	most	_	_	_	_
14-29	1754-1759	often	_	_	_	_
14-30	1760-1763	the	abstract[82]	giv[82]	coref	15-10[89_82]
14-31	1764-1777	leukotoxicity	abstract[82]	giv[82]	_	_
14-32	1778-1780	is	_	_	_	_
14-33	1781-1791	correlated	_	_	_	_
14-34	1792-1796	with	_	_	_	_
14-35	1797-1800	the	abstract[83]	new[83]	_	_
14-36	1801-1804	JP2	abstract[83]	new[83]	_	_
14-37	1805-1807	or	abstract[83]	new[83]	_	_
14-38	1808-1815	non-JP2	abstract[83]	new[83]	_	_
14-39	1816-1824	genotype	abstract[83]	new[83]	_	_
14-40	1825-1827	of	abstract[83]	new[83]	_	_
14-41	1828-1831	the	abstract[83]|abstract[86]	new[83]|giv[86]	ana	15-3[0_86]
14-42	1832-1834	A.	abstract[83]|person|abstract[86]	new[83]|giv|giv[86]	coref	15-14
14-43	1835-1856	actinomycetemcomitans	abstract[83]|person|abstract[86]	new[83]|giv|giv[86]	coref	15-15
14-44	1857-1863	strain	abstract[83]|abstract[86]	new[83]|giv[86]	_	_
14-45	1864-1865	.	_	_	_	_

#Text=Therefore , it has been the common believe that the leukotoxicity of an A. actinomycetemcomitans strain could be explained by the 530-bp deletion , an explanation supported by recent results presented by Sampathkumar and co-workers .
15-1	1866-1875	Therefore	_	_	_	_
15-2	1876-1877	,	_	_	_	_
15-3	1878-1880	it	abstract	giv	coref	15-6[88_0]
15-4	1881-1884	has	_	_	_	_
15-5	1885-1889	been	_	_	_	_
15-6	1890-1893	the	abstract[88]	giv[88]	coref	15-13[92_88]
15-7	1894-1900	common	abstract[88]	giv[88]	_	_
15-8	1901-1908	believe	abstract[88]	giv[88]	_	_
15-9	1909-1913	that	_	_	_	_
15-10	1914-1917	the	abstract[89]	giv[89]	coref	16-11[102_89]
15-11	1918-1931	leukotoxicity	abstract[89]	giv[89]	_	_
15-12	1932-1934	of	abstract[89]	giv[89]	_	_
15-13	1935-1937	an	abstract[89]|abstract[92]	giv[89]|giv[92]	_	_
15-14	1938-1940	A.	abstract[89]|person|abstract[92]	giv[89]|giv|giv[92]	coref	16-3
15-15	1941-1962	actinomycetemcomitans	abstract[89]|person|abstract[92]	giv[89]|giv|giv[92]	coref	16-4
15-16	1963-1969	strain	abstract[89]|abstract[92]	giv[89]|giv[92]	_	_
15-17	1970-1975	could	_	_	_	_
15-18	1976-1978	be	_	_	_	_
15-19	1979-1988	explained	_	_	_	_
15-20	1989-1991	by	_	_	_	_
15-21	1992-1995	the	abstract[93]	giv[93]	appos	15-25[94_93]
15-22	1996-2002	530-bp	abstract[93]	giv[93]	_	_
15-23	2003-2011	deletion	abstract[93]	giv[93]	_	_
15-24	2012-2013	,	_	_	_	_
15-25	2014-2016	an	abstract[94]	giv[94]	coref	16-7[101_94]
15-26	2017-2028	explanation	abstract[94]	giv[94]	_	_
15-27	2029-2038	supported	_	_	_	_
15-28	2039-2041	by	_	_	_	_
15-29	2042-2048	recent	abstract[95]	new[95]	coref	16-15[0_95]
15-30	2049-2056	results	abstract[95]	new[95]	_	_
15-31	2057-2066	presented	_	_	_	_
15-32	2067-2069	by	_	_	_	_
15-33	2070-2082	Sampathkumar	person	new	_	_
15-34	2083-2086	and	_	_	_	_
15-35	2087-2097	co-workers	person	new	_	_
15-36	2098-2099	.	_	_	_	_

#Text=However , A. actinomycetemcomitans strains without the 530-bp deletion with high leukotoxicity according to results obtained by cell lysis assay have been reported on .
16-1	2100-2107	However	_	_	_	_
16-2	2108-2109	,	_	_	_	_
16-3	2110-2112	A.	person|abstract[100]	giv|giv[100]	coref|coref|coref|coref	17-7|17-7[110_100]|17-7|17-7[110_100]
16-4	2113-2134	actinomycetemcomitans	person|abstract[100]	giv|giv[100]	coref	17-8
16-5	2135-2142	strains	abstract[100]	giv[100]	_	_
16-6	2143-2150	without	abstract[100]	giv[100]	_	_
16-7	2151-2154	the	abstract[100]|abstract[101]	giv[100]|giv[101]	_	_
16-8	2155-2161	530-bp	abstract[100]|abstract[101]	giv[100]|giv[101]	_	_
16-9	2162-2170	deletion	abstract[100]|abstract[101]	giv[100]|giv[101]	_	_
16-10	2171-2175	with	abstract[100]|abstract[101]	giv[100]|giv[101]	_	_
16-11	2176-2180	high	abstract[100]|abstract[101]|abstract[102]	giv[100]|giv[101]|giv[102]	_	_
16-12	2181-2194	leukotoxicity	abstract[100]|abstract[101]|abstract[102]	giv[100]|giv[101]|giv[102]	_	_
16-13	2195-2204	according	abstract[100]|abstract[101]	giv[100]|giv[101]	_	_
16-14	2205-2207	to	abstract[100]|abstract[101]	giv[100]|giv[101]	_	_
16-15	2208-2215	results	abstract[100]|abstract[101]|abstract	giv[100]|giv[101]|giv	coref	21-7[152_0]
16-16	2216-2224	obtained	_	_	_	_
16-17	2225-2227	by	_	_	_	_
16-18	2228-2232	cell	place|abstract[106]	giv|new[106]	coref|coref	19-30[128_106]|19-30[128_106]
16-19	2233-2238	lysis	abstract|abstract[106]	giv|new[106]	_	_
16-20	2239-2244	assay	abstract[106]	new[106]	_	_
16-21	2245-2249	have	_	_	_	_
16-22	2250-2254	been	_	_	_	_
16-23	2255-2263	reported	_	_	_	_
16-24	2264-2266	on	_	_	_	_
16-25	2267-2268	.	_	_	_	_

#Text=Furthermore , the leukotoxic potential of A. actinomycetemcomitans strains has been explained by different mechanisms .
17-1	2269-2280	Furthermore	_	_	_	_
17-2	2281-2282	,	_	_	_	_
17-3	2283-2286	the	abstract[107]	new[107]	coref	18-18[115_107]
17-4	2287-2297	leukotoxic	abstract[107]	new[107]	_	_
17-5	2298-2307	potential	abstract[107]	new[107]	_	_
17-6	2308-2310	of	abstract[107]	new[107]	_	_
17-7	2311-2313	A.	abstract[107]|person|abstract[110]	new[107]|giv|giv[110]	coref|coref|coref|coref	20-18|20-31[143_110]|20-18|20-31[143_110]
17-8	2314-2335	actinomycetemcomitans	abstract[107]|person|abstract[110]	new[107]|giv|giv[110]	coref	18-33[119_0]
17-9	2336-2343	strains	abstract[107]|abstract[110]	new[107]|giv[110]	_	_
17-10	2344-2347	has	_	_	_	_
17-11	2348-2352	been	_	_	_	_
17-12	2353-2362	explained	_	_	_	_
17-13	2363-2365	by	_	_	_	_
17-14	2366-2375	different	abstract[111]	new[111]	_	_
17-15	2376-2386	mechanisms	abstract[111]	new[111]	_	_
17-16	2387-2388	.	_	_	_	_

#Text=A higher expression of the mRNA , encoding the ltxA , has been reported to correspond with a higher leukotoxic potential , but also a variation in the activity of LtxA in some A. actinomycetemcomitans has been reported .
18-1	2389-2390	A	abstract[112]	new[112]	coref	19-13[124_112]
18-2	2391-2397	higher	abstract[112]	new[112]	_	_
18-3	2398-2408	expression	abstract[112]	new[112]	_	_
18-4	2409-2411	of	abstract[112]	new[112]	_	_
18-5	2412-2415	the	abstract[112]|object[113]	new[112]|new[113]	coref	19-38[0_113]
18-6	2416-2420	mRNA	abstract[112]|object[113]	new[112]|new[113]	_	_
18-7	2421-2422	,	_	_	_	_
18-8	2423-2431	encoding	_	_	_	_
18-9	2432-2435	the	abstract[114]	giv[114]	coref	18-31[0_114]
18-10	2436-2440	ltxA	abstract[114]	giv[114]	_	_
18-11	2441-2442	,	_	_	_	_
18-12	2443-2446	has	_	_	_	_
18-13	2447-2451	been	_	_	_	_
18-14	2452-2460	reported	_	_	_	_
18-15	2461-2463	to	_	_	_	_
18-16	2464-2474	correspond	_	_	_	_
18-17	2475-2479	with	_	_	_	_
18-18	2480-2481	a	abstract[115]	giv[115]	coref	21-28[160_115]
18-19	2482-2488	higher	abstract[115]	giv[115]	_	_
18-20	2489-2499	leukotoxic	abstract[115]	giv[115]	_	_
18-21	2500-2509	potential	abstract[115]	giv[115]	_	_
18-22	2510-2511	,	_	_	_	_
18-23	2512-2515	but	_	_	_	_
18-24	2516-2520	also	_	_	_	_
18-25	2521-2522	a	abstract[116]	new[116]	_	_
18-26	2523-2532	variation	abstract[116]	new[116]	_	_
18-27	2533-2535	in	abstract[116]	new[116]	_	_
18-28	2536-2539	the	abstract[116]|abstract[117]	new[116]|giv[117]	_	_
18-29	2540-2548	activity	abstract[116]|abstract[117]	new[116]|giv[117]	_	_
18-30	2549-2551	of	abstract[116]|abstract[117]	new[116]|giv[117]	_	_
18-31	2552-2556	LtxA	abstract[116]|abstract[117]|abstract	new[116]|giv[117]|giv	coref	19-14
18-32	2557-2559	in	_	_	_	_
18-33	2560-2564	some	person[119]	giv[119]	coref	19-10[122_119]
18-34	2565-2567	A.	person[119]	giv[119]	_	_
18-35	2568-2589	actinomycetemcomitans	person[119]	giv[119]	_	_
18-36	2590-2593	has	_	_	_	_
18-37	2594-2598	been	_	_	_	_
18-38	2599-2607	reported	_	_	_	_
18-39	2608-2609	.	_	_	_	_

#Text=Only a few studies have compared the leukotoxicity of A. actinomycetemcomitans with the LtxA expression and production defined as a quantification of the LtxA , e. g. , by enzyme-linked immunosorbent assay ( ELISA ) , or mRNA coding for LtxA , but it seems reasonable to assume that the two factors are related .
19-1	2610-2614	Only	_	_	_	_
19-2	2615-2616	a	event[120]	giv[120]	_	_
19-3	2617-2620	few	event[120]	giv[120]	_	_
19-4	2621-2628	studies	event[120]	giv[120]	_	_
19-5	2629-2633	have	_	_	_	_
19-6	2634-2642	compared	_	_	_	_
19-7	2643-2646	the	abstract[121]	new[121]	_	_
19-8	2647-2660	leukotoxicity	abstract[121]	new[121]	_	_
19-9	2661-2663	of	abstract[121]	new[121]	_	_
19-10	2664-2666	A.	abstract[121]|person[122]	new[121]|giv[122]	_	_
19-11	2667-2688	actinomycetemcomitans	abstract[121]|person[122]	new[121]|giv[122]	_	_
19-12	2689-2693	with	abstract[121]|person[122]	new[121]|giv[122]	_	_
19-13	2694-2697	the	abstract[121]|person[122]|abstract[124]	new[121]|giv[122]|giv[124]	coref	20-41[147_124]
19-14	2698-2702	LtxA	abstract[121]|person[122]|object|abstract[124]	new[121]|giv[122]|giv|giv[124]	coref	19-23[126_0]
19-15	2703-2713	expression	abstract[121]|person[122]|abstract[124]	new[121]|giv[122]|giv[124]	_	_
19-16	2714-2717	and	abstract[121]|person[122]	new[121]|giv[122]	_	_
19-17	2718-2728	production	abstract[121]|person[122]|abstract	new[121]|giv[122]|giv	_	_
19-18	2729-2736	defined	_	_	_	_
19-19	2737-2739	as	_	_	_	_
19-20	2740-2741	a	_	_	_	_
19-21	2742-2756	quantification	_	_	_	_
19-22	2757-2759	of	_	_	_	_
19-23	2760-2763	the	object[126]	giv[126]	coref	19-41[0_126]
19-24	2764-2768	LtxA	object[126]	giv[126]	_	_
19-25	2769-2770	,	_	_	_	_
19-26	2771-2773	e.	_	_	_	_
19-27	2774-2776	g.	_	_	_	_
19-28	2777-2778	,	_	_	_	_
19-29	2779-2781	by	_	_	_	_
19-30	2782-2795	enzyme-linked	abstract[128]	giv[128]	ana	19-44[0_128]
19-31	2796-2809	immunosorbent	abstract|abstract[128]	new|giv[128]	_	_
19-32	2810-2815	assay	abstract[128]	giv[128]	_	_
19-33	2816-2817	(	_	_	_	_
19-34	2818-2823	ELISA	person	new	coref	20-38
19-35	2824-2825	)	_	_	_	_
19-36	2826-2827	,	_	_	_	_
19-37	2828-2830	or	_	_	_	_
19-38	2831-2835	mRNA	object	giv	coref	20-47
19-39	2836-2842	coding	_	_	_	_
19-40	2843-2846	for	_	_	_	_
19-41	2847-2851	LtxA	object	giv	coref	20-28
19-42	2852-2853	,	_	_	_	_
19-43	2854-2857	but	_	_	_	_
19-44	2858-2860	it	abstract	giv	coref	20-46[150_0]
19-45	2861-2866	seems	_	_	_	_
19-46	2867-2877	reasonable	_	_	_	_
19-47	2878-2880	to	_	_	_	_
19-48	2881-2887	assume	_	_	_	_
19-49	2888-2892	that	_	_	_	_
19-50	2893-2896	the	abstract[133]	giv[133]	_	_
19-51	2897-2900	two	abstract[133]	giv[133]	_	_
19-52	2901-2908	factors	abstract[133]	giv[133]	_	_
19-53	2909-2912	are	_	_	_	_
19-54	2913-2920	related	_	_	_	_
19-55	2921-2922	.	_	_	_	_

#Text=In the present study , we aimed to investigate if the leukotoxicity of a collection of Ghanaian A. actinomycetemcomitans , serotype b , is related to the LtxA production of the strains determined by Western blotting and ELISA , and LtxA expression as determined in a mRNA expression assay .
20-1	2923-2925	In	_	_	_	_
20-2	2926-2929	the	abstract[134]	new[134]	_	_
20-3	2930-2937	present	abstract[134]	new[134]	_	_
20-4	2938-2943	study	abstract[134]	new[134]	_	_
20-5	2944-2945	,	_	_	_	_
20-6	2946-2948	we	person	acc	ana	21-3
20-7	2949-2954	aimed	_	_	_	_
20-8	2955-2957	to	_	_	_	_
20-9	2958-2969	investigate	_	_	_	_
20-10	2970-2972	if	_	_	_	_
20-11	2973-2976	the	abstract[136]	new[136]	_	_
20-12	2977-2990	leukotoxicity	abstract[136]	new[136]	_	_
20-13	2991-2993	of	abstract[136]	new[136]	_	_
20-14	2994-2995	a	abstract[136]|object[137]	new[136]|new[137]	_	_
20-15	2996-3006	collection	abstract[136]|object[137]	new[136]|new[137]	_	_
20-16	3007-3009	of	abstract[136]|object[137]	new[136]|new[137]	_	_
20-17	3010-3018	Ghanaian	abstract[136]|object[137]	new[136]|new[137]	_	_
20-18	3019-3021	A.	abstract[136]|object[137]|person	new[136]|new[137]|giv	coref	21-37
20-19	3022-3043	actinomycetemcomitans	abstract[136]|object[137]	new[136]|new[137]	_	_
20-20	3044-3045	,	_	_	_	_
20-21	3046-3054	serotype	abstract|object[140]	new|new[140]	_	_
20-22	3055-3056	b	object[140]	new[140]	_	_
20-23	3057-3058	,	_	_	_	_
20-24	3059-3061	is	_	_	_	_
20-25	3062-3069	related	_	_	_	_
20-26	3070-3072	to	_	_	_	_
20-27	3073-3076	the	quantity[142]	new[142]	_	_
20-28	3077-3081	LtxA	abstract|quantity[142]	giv|new[142]	coref	21-32
20-29	3082-3092	production	quantity[142]	new[142]	_	_
20-30	3093-3095	of	quantity[142]	new[142]	_	_
20-31	3096-3099	the	quantity[142]|abstract[143]	new[142]|giv[143]	_	_
20-32	3100-3107	strains	quantity[142]|abstract[143]	new[142]|giv[143]	_	_
20-33	3108-3118	determined	_	_	_	_
20-34	3119-3121	by	_	_	_	_
20-35	3122-3129	Western	object[144]	new[144]	_	_
20-36	3130-3138	blotting	object[144]	new[144]	_	_
20-37	3139-3142	and	_	_	_	_
20-38	3143-3148	ELISA	abstract	giv	coref	21-11
20-39	3149-3150	,	_	_	_	_
20-40	3151-3154	and	_	_	_	_
20-41	3155-3159	LtxA	person|abstract[147]	new|giv[147]	coref|coref	20-48[0_147]|20-48[0_147]
20-42	3160-3170	expression	abstract[147]	giv[147]	_	_
20-43	3171-3173	as	_	_	_	_
20-44	3174-3184	determined	_	_	_	_
20-45	3185-3187	in	_	_	_	_
20-46	3188-3189	a	abstract[150]	giv[150]	coref	21-13[156_150]
20-47	3190-3194	mRNA	object|abstract[150]	giv|giv[150]	coref	21-13
20-48	3195-3205	expression	abstract|abstract[150]	giv|giv[150]	coref	21-14
20-49	3206-3211	assay	abstract[150]	giv[150]	_	_
20-50	3212-3213	.	_	_	_	_

#Text=Furthermore , we wanted to compare the results obtained by ELISA and mRNA expression assay to elucidate the relationship between the two quantification methods used to determine leukotoxic potential as the LtxA production and expression of A. actinomycetemcomitans , respectively .
21-1	3214-3225	Furthermore	_	_	_	_
21-2	3226-3227	,	_	_	_	_
21-3	3228-3230	we	person	giv	_	_
21-4	3231-3237	wanted	_	_	_	_
21-5	3238-3240	to	_	_	_	_
21-6	3241-3248	compare	_	_	_	_
21-7	3249-3252	the	abstract[152]	giv[152]	_	_
21-8	3253-3260	results	abstract[152]	giv[152]	_	_
21-9	3261-3269	obtained	_	_	_	_
21-10	3270-3272	by	_	_	_	_
21-11	3273-3278	ELISA	abstract	giv	_	_
21-12	3279-3282	and	_	_	_	_
21-13	3283-3287	mRNA	abstract|abstract[156]	giv|giv[156]	_	_
21-14	3288-3298	expression	abstract|abstract[156]	giv|giv[156]	_	_
21-15	3299-3304	assay	abstract[156]	giv[156]	_	_
21-16	3305-3307	to	_	_	_	_
21-17	3308-3317	elucidate	_	_	_	_
21-18	3318-3321	the	abstract[157]	new[157]	_	_
21-19	3322-3334	relationship	abstract[157]	new[157]	_	_
21-20	3335-3342	between	abstract[157]	new[157]	_	_
21-21	3343-3346	the	abstract[157]|abstract[159]	new[157]|new[159]	_	_
21-22	3347-3350	two	abstract[157]|abstract[159]	new[157]|new[159]	_	_
21-23	3351-3365	quantification	abstract[157]|abstract|abstract[159]	new[157]|new|new[159]	_	_
21-24	3366-3373	methods	abstract[157]|abstract[159]	new[157]|new[159]	_	_
21-25	3374-3378	used	_	_	_	_
21-26	3379-3381	to	_	_	_	_
21-27	3382-3391	determine	_	_	_	_
21-28	3392-3402	leukotoxic	abstract[160]	giv[160]	_	_
21-29	3403-3412	potential	abstract[160]	giv[160]	_	_
21-30	3413-3415	as	abstract[160]	giv[160]	_	_
21-31	3416-3419	the	abstract[160]	giv[160]	_	_
21-32	3420-3424	LtxA	abstract[160]|abstract	giv[160]|giv	_	_
21-33	3425-3435	production	abstract[160]	giv[160]	_	_
21-34	3436-3439	and	abstract[160]	giv[160]	_	_
21-35	3440-3450	expression	abstract[160]	giv[160]	_	_
21-36	3451-3453	of	abstract[160]	giv[160]	_	_
21-37	3454-3456	A.	abstract[160]|person	giv[160]|giv	_	_
21-38	3457-3478	actinomycetemcomitans	abstract[160]	giv[160]	_	_
21-39	3479-3480	,	abstract[160]	giv[160]	_	_
21-40	3481-3493	respectively	abstract[160]	giv[160]	_	_
21-41	3494-3495	.	_	_	_	_
